CAC
Cowen and Company Portfolio holdings
AUM
$2.9B
This Quarter Return
+10.52%
1 Year Return
+104.28%
3 Year Return
+119.87%
5 Year Return
+632.2%
10 Year Return
–
AUM
$1.21B
AUM Growth
+$1.21B
(+42%)
Cap. Flow
+$342M
Cap. Flow
% of AUM
28.32%
Top 10 Holdings %
Top 10 Hldgs %
40.06%
Holding
735
New
182
Increased
169
Reduced
183
Closed
147
Top Buys
| 1 |
NVIDIA
NVDA
|
$81.5M |
| 2 |
Protagonist Therapeutics
PTGX
|
$45.8M |
| 3 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
$45.2M |
| 4 |
Tarsus Pharmaceuticals
TARS
|
$36.1M |
| 5 |
PTC Therapeutics
PTCT
|
$32.5M |
Top Sells
| 1 |
Sylvamo
SLVM
|
$99.5M |
| 2 |
KVSC
Khosla Ventures Acquisition Co. III Class A Common Stock
KVSC
|
$24.5M |
| 3 |
TIOA
Tio Tech A Class A Ordinary Share
TIOA
|
$22.2M |
| 4 |
Immunovant
IMVT
|
$19.4M |
| 5 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$17.6M |
Sector Composition
| 1 | Healthcare | 36.03% |
| 2 | Financials | 28.83% |
| 3 | Technology | 9.92% |
| 4 | Energy | 5.75% |
| 5 | Consumer Discretionary | 4.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
NVIDIA
NVDA
$4.24T
| $81.5M | 6.76% | +192,750 | New | +$81.5M |
|
2
Establishment Labs
ESTA
$1.2B
| $66.3M | 5.49% | 966,172 +100,000 | +12% | +$6.86M |
|
3
Avidity Biosciences
RNA
$5.99B
| $62.4M | 5.17% | 5,629,103 +1,036,137 | +23% | +$11.5M |
|
|
4
Protagonist Therapeutics
PTGX
$3.67B
| $45.8M | 3.79% | +1,657,551 | New | +$45.8M |
|
|
MMP
5
DELISTED
Magellan Midstream Partners, L.P.
MMP
| $45.2M | 3.75% | +725,000 | New | +$45.2M |
|
|
AVDL
6
Avadel Pharmaceuticals
AVDL
$1.43B
| $43.9M | 3.64% | 2,664,076 -1,068,702 | -29% | -$17.6M |
|
7
Stoke Therapeutics
STOK
$1.08B
| $39.6M | 3.28% | 3,721,659 +442,517 | +13% | +$4.7M |
|
|
8
Tarsus Pharmaceuticals
TARS
$2.47B
| $36.1M | 2.99% | +1,999,383 | New | +$36.1M |
|
|
9
PTC Therapeutics
PTCT
$3.92B
| $32.5M | 2.7% | +799,511 | New | +$32.5M |
|
|
AAC
10
DELISTED
Ares Acquisition Corporation
AAC
| $29.9M | 2.48% | 2,831,626 +1,527,398 | +117% | +$16.1M |
|
11
Immunocore
IMCR
$1.62B
| $27.6M | 2.29% | 460,036 +54,862 | +14% | +$3.29M |
|
12
Sumitomo Mitsui Financial
SMFG
$105B
| $24.1M | 2% | 2,800,730 | – | – |
|
13
Rocket Pharmaceuticals
RCKT
$354M
| $21.9M | 1.81% | 1,100,000 | – | – |
|
|
PEGR
14
DELISTED
Project Energy Reimagined Acquisition Corp. Class A Ordinary Share
PEGR
| $18.7M | 1.55% | 1,809,614 +309,614 | +21% | +$3.21M |
|
15
scPharmaceuticals
SCPH
$295M
| $18.7M | 1.55% | 1,837,918 -969,644 | -35% | -$9.88M |
|
16
Energy Transfer Partners
ET
$60.8B
| $18.2M | 1.51% | 1,435,000 +50,500 | +4% | +$641K |
|
|
RRAC
17
DELISTED
Rigel Resource Acquisition Corp.
RRAC
| $16.6M | 1.37% | +1,547,134 | New | +$16.6M |
|
|
HCVIU
18
DELISTED
Hennessy Capital Investment Corp. VI Unit
HCVIU
| $15.4M | 1.28% | 1,500,000 | – | – |
|
|
EOCW
19
DELISTED
Elliott Opportunity II Corp.
EOCW
| $15.2M | 1.26% | +1,463,962 | New | +$15.2M |
|
20
Innoviz Technologies
INVZ
$335M
| $14.2M | 1.18% | 5,015,833 +319,724 | +7% | +$908K |
|
21
AdvisorShares Pure US Cannabis ETF
MSOS
$986M
| $14.2M | 1.18% | 2,566,280 +998,000 | +64% | +$5.53M |
|
22
Meta Platforms (Facebook)
META
$1.86T
| $12.2M | 1.01% | 42,542 +27,430 | +182% | +$7.87M |
|
|
DNAD
23
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
| $11.4M | 0.95% | 1,104,200 +1,050,300 | +1,949% | +$10.9M |
|
24
Coinbase
COIN
$78.2B
| $11.4M | 0.95% | 159,352 +25,506 | +19% | +$1.82M |
|
25
Mercer International
MERC
$223M
| $11.3M | 0.94% | +1,400,000 | New | +$11.3M |
|